Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular Read All » View HTML
Toggle Summary No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for Read All » View HTML
Toggle Summary First Clinical Trial Investigating the Combination of Allogeneic Donor NK Cell Therapy and FDA-Approved Targeted Monoclonal Antibody Therapy for Solid Tumor Malignancies SAN DIEGO , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company Read All » View HTML
Toggle Summary Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100 SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer Read All » View HTML
Toggle Summary Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m. Read All » View HTML
Toggle Summary $4.0 Million Awarded by CIRM to Support Advancement of First-of-Kind NK Cell Product Candidate derived from a Master Engineered iPSC Line SAN DIEGO , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All » View HTML
Toggle Summary No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission Read All » View HTML
Toggle Summary Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated Read All » View HTML
Toggle Summary SAN DIEGO , May 02, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Chief Scientific Officer, will Read All » View HTML
Toggle Summary SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML